Moreover,
Lama antibodies: new therapeutic track:
If the current treatments of schizophrenia – mental illness affecting 1% of the world’s population – helps reduce certain symptoms. Similarly, they are very little act on cognitive disorders affecting the daily life of patients. Nevertheless,
Scientists from the Institute of Functional Genomics (CNRS/Inserm/University of Montpellier) have just designed a nanocorps from llamas antibodies. Therefore, capable of specifically activating a glutamate receptor involved in the regulation of neurons activity. Meanwhile, Can be administered by venous. muscular route peripherally, this new molecule has demonstrated its ability to cross the blood-brain barrier and effectively reach their receptors in the brain.
The therapeutic effect of these nanocorps was evaluated in two preclinical models of schizophrenia. The administration of the nanocorps made it possible to correct the cognitive disorders observed in these two murine models: the cognitive functions of the animals are clearly improved from the first injection. lama antibodies: new therapeutic track with a prolonged effect for more than a week.
Clinical studies will now be necessary to demonstrate that this ability to correct cognitive disorders via a peripheral injection can. constitute a new path of treatment for schizophrenia. This work confirms the potential of nanocorps as a new therapeutic strategy to act on the brain. their use can ultimately be extended to the treatment of other neurological diseases.
© Bruno Jourdain / IGE / CNRS Images
lama antibodies: new therapeutic track — Lama antibodies: new therapeutic track: If the current treatments of schizophrenia – mental illness affecting 1% of the world’s population – helps reduce certain symptoms. they are very little act on cognitive disorders affecting the daily life of patients. Scientists from the In.
lama antibodies: new therapeutic track
Further reading: When the shortage of biotherapies puts lives in danger – An emergency center for headaches in Paris, puffed with hope for the patients – The resurgence of hepatitis cases has worried local health authorities – Eclosion of measles in the Sussex region – Valneva: EMA rises the suspension on IXCHIQ in those over 65.
